CRBU Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 112531 min ago

@ $6.80

Išleistas: 14 vas. 2024 @ 21:06

Grąža: -46.47%

Ankstesnis signalas: vas. 14 - 16:30

Ankstesnis signalas: Pardavimas

Grąža: 2.45 %

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 23:00):

Stats
Šios dienos apimtis	2.30M
Vidutinė apimtis	1.58M
Rinkos kapitalizacija	328.76M
EPS	$0 ( 2024-03-14 )
Kita pelno data	( $-0.390 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.64
ATR14	$0.00800 (0.22%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-20	O'byrne Jason	Buy	153 000	Option to purchase Common Stock
2024-02-20	O'byrne Jason	Buy	33 000	Common Stock
2024-02-20	Mcclung Barbara G	Buy	33 000	Common Stock
2024-02-20	Mcclung Barbara G	Buy	153 000	Option to purchase Common Stock
2024-02-20	Khan Ruhi Ahmad	Buy	153 000	Option to purchase Common Stock

INSIDER POWER
93.35
Last 96 transactions
Buy: 4 096 718 \| Sell: 409 985

Tūris Koreliacija

Ilgas: 0.29 (neutral)

Trumpas: 0.37 (neutral)

Signal:(57.899) Neutral

Caribou Biosciences, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
GLSI	0.945
ARVL	0.935
MICS	0.932
SATL	0.931
SXTC	0.931
NRXP	0.931
CSSE	0.93
STIM	0.927
GMVD	0.926
JAGX	0.924

10 Labiausiai neigiamai susiję koreliacijos
LSCC	-0.951
PPYAU	-0.929
PDFS	-0.927
SNPS	-0.927
HEWG	-0.923
SMH	-0.922
SNSR	-0.922
MCHP	-0.921
INSE	-0.919
CCRC	-0.919

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Caribou Biosciences, Inc. Koreliacija - Valiuta/Žaliavos

-0.79
( moderate negative )

-0.67
( moderate negative )

0.00
( neutral )

-0.75
( moderate negative )

0.76
( moderate )

Caribou Biosciences, Inc. Finansinės ataskaitos

Annual	2023
Pajamos:	$34.48M
Bruto pelnas:	$30.95M (89.78 %)
EPS:	$-1.380

FY	2023
Pajamos:	$34.48M
Bruto pelnas:	$30.95M (89.78 %)
EPS:	$-1.380

FY	2022
Pajamos:	$13.85M
Bruto pelnas:	$10.21M (73.71 %)
EPS:	$-1.640

FY	2021
Pajamos:	$9.60M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-2.95

Financial Reports:

No articles found.

Caribou Biosciences, Inc.

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.